ASH2018 注目テーマ Plenary Session #1

Luspaterceptによって、低リスクMDSの
赤血球輸血依存の回避が高い割合で達成 The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Alan F. List（Moffitt Cancer Center, Tampa, FL）